Oral squamous cell carcinoma (OSCC) is a common type of cancer characterized by a low survival rate, mostly due to local recurrence and metastasis. In view of the importance of predicting tumor behavior in the choice of treatment strategies for OSCC, several studies have attempted to investigate the prognostic value of tissue biomarkers, including microRNA (miRNA). The purpose of this study was to perform a systematic review and meta-analysis to evaluate the relationship between miRNA expression and survival of OSCC patients. Studies were identified by searching on MEDLINE/PubMed, SCOPUS, Web of Science, and Google Scholar. Quality assessment of studies was performed with the Newcastle-Ottawa Scale. Data were collected from cohort studies comparing disease-free survival and overall survival in patients with high miRNA expression compared to those with low expression. A total of 15 studies featuring 1,200 OSCC samples, predominantly from Asia, met the inclusion criteria and were included in the meta-analysis. Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b). The pooled hazard ratio values (95% confidence interval) related to different miRNA expression for overall survival and disease-free survival were 2.65 (2.07–3.39) and 1.95 (1.28–2.98), respectively. The results of this meta-analysis revealed that the expression levels of specific miRNAs can robustly predict prognosis of OSCC patients.
BabaOHasegawaSNagaiHUchidaFYamatojiMKannoNIYamagataKSakaiSYanagawaTBukawaH. 2016. MicroRNA-155-5p is associated with oral squamous cell carcinoma metastasis and poor prognosis. J Oral Pathol Med. 45(4):248–255.
2.
Behm-AnsmantIRehwinkelJIzaurraldeE. 2006. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530.
3.
BituCCDestroMFCarreraMda SilvaSDGranerEKowalskiLPSoaresFAColettaRD. 2012. Hoxa1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis. BMC Cancer. 12:146.
4.
BradburnMJClarkTGLoveSBAltmanDG. 2003. Survival analysis part II: multivariate data analysis—an introduction to concepts and methods. Br J Cancer. 89(3):431–436.
5.
BufalinoACervigneNKde OliveiraCEFonsecaFPRodriguesPCMacedoCCSobralLMMiguelMCLopesMAPaes LemeAFet al. 2015. Low miR-143/miR-145 cluster levels induce activin a overexpression in oral squamous cell carcinomas, which contributes to poor prognosis. PLoS One. 10(8):e0136599.
6.
CastilhoRMSquarizeCHAlmeidaLO. 2017. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 18(7). pii: e1506.
7.
ChangCCYangYJLiYJChenSTLinBRWuTSLinSKKuoMYTanCT. 2013. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol. 49(9):923–931.
8.
ChengCMShiahSGHuangCCHsiaoJRChangJY. 2016. Up-regulation of miR-455-5p by the TGF-β-SMAD signalling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. J Pathol. 240(1):38–49.
9.
CirilloNHassonaYCelentanoALimKPManchellaSParkinsonEKPrimeSS. 2017. Cancer-associated fibroblasts regulate keratinocyte cell-cell adhesion via TGF-β-dependent pathways in genotype-specific oral cancer. Carcinogenesis. 38(1):76–85.
10.
DengLLiuH. 2015. MicroRNA-506 suppresses growth and metastasis of oral squamous cell carcinoma via targeting GATA6. Int J Clin Exp Med. 8(2):1862–1870.
11.
FriedmanRCFarhKKBurgeCBBartelDP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1):92–105.
12.
GanciFSacconiAMancioccoVSperdutiIBattagliaPCovelloRMutiPStranoSSprianoGFontemaggiGet al. 2016. MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head Neck. 38(Suppl 1):e189–e197.
13.
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548.
14.
HedbackNJensenDHSpechtLFiehnAMTherkildsenMHFriis-HansenLDabelsteenEvon BuchwaldC. 2014. MiR-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survival. PLoS One. 9(4):e95193.
HigginsJPTGreenS. 2008. Cochrane handbook for systematic reviews of interventions. Chichester (UK): Wiley-Blackwell.
17.
HouYYYouJJYangCMPanHWChenHCLeeJHLinYSLiouHHLiuPFChiCCet al. 2016. Aberrant DNA hypomethylation of miR-196b contributes to migration and invasion of oral cancer. Oncol Lett. 11(6):4013–4021.
18.
HuJXuJFGeWL. 2016. MiR-497 enhances metastasis of oral squamous cell carcinoma through SMAD7 suppression. Am J Transl Res. 8(7):3023–3031.
19.
Le CampionACOVRibeiroCMBLuizRRdaSilvaJúniorFFBarrosHCSDos SantosKCBFerreiraSJGonçalvesLSFerreiraSMS. 2017. Low survival rates of oral and oropharyngeal squamous cell carcinoma. Int J Dent. 2017:5815493.
20.
LiaoLWangJOuyangSZhangPWangJZhangM. 2015. Expression and clinical significance of microRNA-1246 in human oral squamous cell carcinoma. Med Sci Monit. 21:776–781.
21.
LiberatiAAltmanDGTetzlaffJMulrowCGotzschePCIoannidisJPClarkeMDevereauxPJKleijnenJMoherD. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 62(10):e1–e34.
22.
LimKPCirilloNHassonaYWeiWThurlowJKCheongSCPitiyageGParkinsonEKPrimeSS. 2011. Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma. J Pathol. 223(4):459–469.
23.
LingenMWPintoAMendesRAFranchiniRCzerninskiRTilakaratneWMPartridgeMPetersonDEWooSB. 2011. Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis. 17(Suppl 1):7–22.
24.
LiuCJTsaiMMTuHFLuiMTChengHWLinSC. 2013. miR-196a overexpression and miR-196a2 gene polymorphism are prognostic predictors of oral carcinomas. Ann Surg Oncol. 20(Suppl 3):S406–S414.
25.
LuMChenWHWangCYMaoCQWangJ. 2017. Reciprocal regulation of miR-1254 and c-Myc in oral squamous cell carcinoma suppresses EMT-mediated metastasis and tumor-initiating properties through MAPK signaling. Biochem Biophys Res Commun. 484(4):801–807.
26.
PengQZhangXMinMZouLShenPZhuY. 2017. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget. 8(27):44893–44909.
27.
Ramos-GarciaPGil-MontoyaJAScullyCAyenAGonzalez-RuizLNavarro-TrivinoFJGonzalez-MolesMA. 2017. An update on the implications of cyclin D1 in oral carcinogenesis. Oral Dis. 23(7):897–912.
28.
RastogiBKumarARautSKPandaNKRattanVJoshiNKhullarM. 2017. Downregulation of miR-377 promotes oral squamous cell carcinoma growth and migration by targeting HDAC9. Cancer Invest. 35(3):152–162.
29.
SasahiraTKuriharaMBhawalUKUedaNShimomotoTYamamotoKKiritaTKuniyasuH. 2012. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer. 107(4):700–706.
30.
ShiLJZhangCYZhouZTMaJYLiuYBaoZXJiangWW. 2015. MicroRNA-155 in oral squamous cell carcinoma: overexpression, localization, and prognostic potential. Head Neck. 37(7):970–976.
31.
ShieldKDFerlayJJemalASankaranarayananRChaturvediAKBrayFSoerjomataramI. 2017. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 67(1):51–64.
32.
ShiibaMShinozukaKSaitoKFushimiKKasamatsuAOgawaraKUzawaKItoHTakiguchiYTanzawaH. 2013. MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma. Br J Cancer. 108(9):1817–1821.
33.
TierneyJFStewartLAGhersiDBurdettSSydesMR. 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:16.
34.
TroianoGBoldrupLArditoFGuXLoMuzioLNylanderK. 2016. Circulating miRNAs from blood, plasma or serum as promising clinical biomarkers in oral squamous cell carcinoma: a systematic review of current findings. Oral Oncol. 63:30–37.
35.
TuHFChangKWChengHWLiuCJ. 2015. Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas. Laryngoscope. 125(11):e365–e370.
36.
VigneswaranNWilliamsMD. 2014. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 26(2):123–141.
37.
WongNKhwajaSSBakerCMGayHAThorstadWLDalyMDLewisJSJrWangX. 2016. Prognostic microRNA signatures derived from the cancer genome atlas for head and neck squamous cell carcinomas. Cancer Med. 5(7):1619–1628.
38.
WuBLeiDWangLYangXJiaSYangZShanCYangXZhangCLuB. 2016. MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. Am J Cancer Res. 6(6):1396–1407.
39.
YangCCHungPSWangPWLiuCJChuTHChengHWLinSC. 2011. MiR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med. 40(5):397–404.
40.
YangCNDengYTTangJYChengSJChenSTLiYJWuTSYangMHLinBRKuoMYet al. 2015. MicroRNA-29b regulates migration in oral squamous cell carcinoma and its clinical significance. Oral Oncol. 51(2):170–177.
41.
YoonAJWangSShenJRobineNPhiliponeEOsterMWNamASantellaRM. 2014. Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am J Transl Res. 6(5):580–592.
42.
YuCCChenPNPengCYYuCHChouMY. 2016. Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis. Oncotarget. 7(15):20180–20192.
43.
YuEHTuHFWuCHYangCCChangKW. 2017. MicroRNA-21 promotes perineural invasion and impacts survival in patients with oral carcinoma. J Chin Med Assoc. 80(6):383–388.
44.
ZanaruddinSNYeePSHorSYKongYHGhaniWMMustafaWMZainRBPrimeSSRahmanZACheongSC. Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin. PLoS One. 2013;8(11):e80229.
45.
ZhangDNiZXuXXiaoJ. 2014. MiR-32 functions as a tumor suppressor and directly targets EZH2 in human oral squamous cell carcinoma. Med Sci Monit. 20:2527–2535.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
